Botulinum-Toxin-AIatrogenic botulism, off-label use and overdose: 7 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2038卷 / 1期

关键词：

D O I：

10.1007/s40278-024-72172-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：63 / 63

相关论文

共 50 条

[21] DalbavancinVarious toxicities, lack of efficacy and off-label use: 7 case reports
Reactions Weekly, 2022, 1925 (1) : 199 - 199
[22] AntineoplasticsVarious toxicities, off-label use and lack of efficacy: 7 case reports
Reactions Weekly, 2022, 1912 (1) : 72 - 72
[23] Prednisone/rituximabSteroid dependence and off-label use of rituximab: 7 case reports
Reactions Weekly, 2021, 1837 (1) : 598 - 598
[24] DanazolVarious toxicities and no response following off-label use: 7 case reports
Reactions Weekly, 2024, 2038 (1) : 106 - 106
[25] AdalimumabLack of efficacy and off-label use: case reports
Reactions Weekly, 2023, 1972 (1) : 19 - 19
[26] Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art
Lewandowski, Milosz
Swierczewska, Zuzanna
Baranska-Rybak, Wioletta
MOLECULES, 2022, 27 (10):
[27] Botulinum toxin ATemporary weak paresis following an off label use: 3 case reports
Reactions Weekly, 2019, 1780 (1) : 76 - 76
[28] Off-label use of botolinum toxin
Truong, D.
JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (07) : CXI - CXI
[29] RamucirumabVarious toxicities following off-label use in hepatocellular carcinoma: 7 case reports
Reactions Weekly, 2021, 1857 (1) : 298 - 298
[30] RetigabineWithdrawal seizures and urinary retention following off-label use: 7 case reports
Reactions Weekly, 2023, 1975 (1) : 328 - 328

← 1 2 3 4 5 →